Patent Win in Japan Paves Way but Raises Questions on Global Rollout for PromarkerEndo

A Breakthrough in Endometriosis Diagnosis

Proteomics International Laboratories Ltd (ASX – PIQ) has secured its first patent for PromarkerEndo, a proprietary blood test aimed at the early diagnosis of endometriosis. The Japan Patent Office granted the patent, marking the first global intellectual property protection for this innovative diagnostic technology. This milestone not only validates the novelty of PromarkerEndo but also positions the company strategically within one of the world’s largest healthcare markets.

Strategic Importance of the Japanese Patent

Japan’s healthcare market is the fourth largest globally and highly advanced in precision medicine and in vitro diagnostics. Securing patent protection here until 2041 provides Proteomics International with a strong foothold for commercialisation efforts, including potential partnerships, licensing deals, and regulatory progress. Managing Director Dr Richard Lipscombe highlighted the significance of this achievement, emphasizing Japan’s role as a key step in the company’s global expansion strategy.

Clinical Validation and Market Potential

PromarkerEndo has demonstrated high accuracy in published clinical studies for detecting endometriosis, including in its early stages. This is particularly important given the current diagnostic challenge – endometriosis affects one in nine women and girls worldwide, yet diagnosis often takes an average of seven years, typically requiring invasive surgery. The blood test offers a less invasive, faster alternative that could transform patient outcomes and reduce healthcare costs.

Global Patent Pursuit and Future Outlook

Beyond Japan, Proteomics International is actively pursuing patent protection in multiple key jurisdictions, including Australia, Canada, China, Europe, India, Singapore, South Korea, and the United States. These efforts underscore the company’s ambition to establish PromarkerEndo as a global standard for endometriosis diagnosis. The granted patent in Japan strengthens the company’s intellectual property portfolio and lays the groundwork for future regulatory approvals and commercial partnerships.

Implications for Investors and Healthcare

This patent grant is a clear signal of Proteomics International’s progress in addressing a significant unmet medical need with a novel diagnostic tool. For investors, it enhances confidence in the company’s technology and commercial pathway. For the healthcare sector, it promises a potential shift in how endometriosis is diagnosed, moving away from invasive procedures toward accessible blood testing.